Teicoplanin
A glycopeptide antibiotic used widely outside the US
Teicoplanin is a glycopeptide antibiotic closely related to vancomycin, used outside the US for serious Gram-positive infections such as MRSA. A meta-analysis of randomised trials found it as effective as vancomycin with fewer adverse events, including less kidney damage. It has never been approved by FDA.
Used in human trials: 10-12 mg/kg, Every 12 hours for 5 loading doses, Intravenous (Study: loading to reach troughs of 15-30 mg/L (normal kidney function)) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
Work out syringe units → · New to syringes? · All dosing data ↓ · Dose and vial tracker · Is this vial OK?
What is it?
Vancomycin and teicoplanin are the two glycopeptides in clinical use for infections caused by invasive beta-lactam-resistant Gram-positive organisms, as a 2009 meta-analysis puts it. Teicoplanin is used outside the US, but an openFDA search of Drugs@FDA finds no US approval, so American clinicians use vancomycin or newer lipoglycopeptides such as dalbavancin, oritavancin and telavancin instead.
A meta-analysis of randomised trials comparing the two found teicoplanin not inferior to vancomycin for efficacy, with significantly fewer total adverse events (risk ratio 0.61), less nephrotoxicity (risk ratio 0.44) and less red man syndrome. Real-world data agree on the kidneys: in matched older patients, nephrotoxicity was 16% on teicoplanin against 32% on vancomycin. In nosocomial pneumonia, pooled trials found linezolid and the glycopeptides, vancomycin or teicoplanin, gave similar clinical cure rates.
Not every comparison favours it. In one hospital's MRSA pneumonia patients, teicoplanin failed far more often than vancomycin, with higher mortality, although vancomycin caused more side effects. As surgical prophylaxis it offered no advantage over a cheaper standard: in prosthetic vascular surgery, infection and mortality were similar to cefazolin.
Getting enough drug into the blood early matters. One study found that reaching trough concentrations of 15 to 30 mg/L required five loading doses at 12-hour intervals in patients with normal kidney function, and patients at or above 15 mg/L tended to respond better (80.9% against 68.6%). Older adults on low-dose regimens were mostly underdosed in the first week, and in children troughs below 10 mg/L halved treatment success. That is why levels are monitored.
Mechanism of Action
Teicoplanin is a glycopeptide antibiotic, like vancomycin, used against resistant Gram-positive bacteria such as MRSA.
Cell wall blocked
Like vancomycin, it binds the building blocks of the bacterial cell wall and stops Gram-positive bacteria building it.
Gram-positive only
Used for MRSA and other beta-lactam-resistant Gram-positive infections, including bacteraemia, pneumonia and catheter infections.
Level-guided
Needs several loading doses to reach target troughs; levels are monitored, especially in older adults, children and kidney impairment.
Published Research
Studies of teicoplanin, from their PubMed abstracts.
Against vancomycin: meta-analysis
Across randomised trials, teicoplanin was not inferior to vancomycin for efficacy, with fewer total adverse events (RR 0.61), less nephrotoxicity (RR 0.44) and less red man syndrome.
Loading doses and trough levels
Five loading doses of 10-12 mg/kg at 12-hour intervals were needed to reach troughs of 15-30 mg/L; patients at 15 mg/L or more tended to respond better (80.9% vs 68.6%), with nephrotoxicity of 1.3% and 3.3% across regimens.
Nosocomial pneumonia vs linezolid
Across nine trials (2,329 patients), linezolid and the glycopeptides vancomycin or teicoplanin gave similar clinical cure (RR 1.01) and microbiological eradication.
MRSA bacteraemia vs linezolid
A meta-analysis of 5,328 patients found linezolid's effectiveness and adverse events comparable to vancomycin, teicoplanin or daptomycin for MRSA bacteraemia.
Nosocomial pneumonia: twelve trials
Across twelve randomised trials of linezolid against vancomycin or teicoplanin, clinical cure did not differ significantly (RR 1.08, p = 0.06), but microbiological eradication was better with linezolid.
Prophylaxis in vascular surgery: against cefazolin
Infection rates and mortality were similar with teicoplanin and cefazolin prophylaxis; cefazolin cost far less, and the authors kept it as the drug of choice for clean vascular surgery.
Kidneys in older patients
In 186 propensity-matched older patients, nephrotoxicity occurred in 16.1% on teicoplanin against 32.3% on vancomycin; longer exposure and higher baseline creatinine raised the risk.
MRSA pneumonia: vancomycin did better
In 116 patients with MRSA pneumonia, clinical failure was 61.3% on teicoplanin against 25.9% on vancomycin and mortality 19.4% against 3.7%, though vancomycin caused more drug changes for side effects (24.1% against 1.6%).
Older adults are underdosed
In 204 older patients, two-thirds had suboptimal levels in the first week on mostly low-dose regimens; thrombocytopenia occurred in 31.5%, nephrotoxicity in 12.5% and hepatotoxicity in 4.1%.
Standard doses in children
In a paediatric cohort, standard dosing reached target levels early; nearly half of samples exceeded 60 mg/L total, yet no nephrotoxicity was seen, which the authors attribute to normal albumin keeping free drug in range.
Lock therapy for port infections
In 22 children with cancer and port-related coagulase-negative staphylococcal bacteraemia, teicoplanin lock therapy saved 72.7% of ports, with cultures clearing in about 4 days.
Kidney injury with piperacillin-tazobactam
Across five cohort studies of 908 patients, piperacillin-tazobactam plus teicoplanin was linked to less acute kidney injury than the same drug plus vancomycin (odds ratio 0.52), with no difference in 30-day mortality. The studies were observational.
MRSA in Chinese patients
A meta-analysis of 12 studies found teicoplanin and vancomycin similar for clinical cure, microbiological cure and adverse events in MRSA infection.
Target levels in children
Across 12 studies and 830 children, troughs under 10 mg/L cut treatment success (50.0% against 95.7%), while troughs under 20 mg/L were linked to less nephrotoxicity.
Dosing Data
There is no US label. One study needed five loading doses of 10 to 12 mg/kg every 12 hours to reach target troughs; after that, dosing is guided by trough levels.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no label and no published test that says what forms or vial sizes Teicoplanin is sold in. A vial's own label is a seller's claim, not a source.
Mixing a vial: a worked example
No worked example: none of the doses on this page is a fixed amount in mg or mcg injected under the skin or into a muscle (the routes given are: intravenous). There is no home-mixing step to show. The reconstitution calculator does the arithmetic for any vial.
Source: the route and amount of each dose row in Dosing Data below.
Storage before and after mixing
Unknown: no label or published stability study on file says how to store Teicoplanin, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Teicoplanin stays intact once mixed.
How it is taken
As it was given in human studies: Intravenous (Every 12 hours for 5 loading doses; Study: loading to reach troughs of 15-30 mg/L (normal kidney function)).
For injection technique, sites and needle disposal, see the mixing guide.
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Study: loading to reach troughs of 15-30 mg/L (normal kidney function): Course of infection.
When effects appear: unknown; no source on this page gives a time to effect for Teicoplanin. Results reported in the studies are under Published Research.
Source: Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Fewer adverse events, less nephrotoxicity and less red man syndrome than vancomycin. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Teicoplanin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
- warfarin: PT-INR rose a median 80.9% after teicoplanin was added, against 30.6% with vancomycin, in a retrospective study of 49 patients; monitor INR
- tacrolimus: both are nephrotoxic; with drug monitoring of each, a 2-fold creatinine rise occurred in 2 of 67 stem cell transplant patients, reversibly
Every peptide's record, with its source: the interaction matrix.
Source: human study, PMID 28674307; human study, PMID 24494811.
Checking what you bought
Unknown: no published independent test of Teicoplanin products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: Not FDA Approved (Not approved by FDA: an openFDA Drugs@FDA search for teicoplanin returned no records (October 3, 2026)). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
No US label; it is not approved in the US.
Legal Status
Teicoplanin is not approved in the US.
Frequently Asked Questions
?Is teicoplanin the same as vancomycin?
No, but they are close relatives: both are glycopeptide antibiotics that block cell-wall building in Gram-positive bacteria.
?Is teicoplanin safer than vancomycin?
In a meta-analysis of randomised trials it caused fewer adverse events overall, less kidney damage and less red man syndrome, with similar effectiveness.
?Why isn't teicoplanin available in the US?
It has no FDA approval; Drugs@FDA lists no teicoplanin product. It is used in Europe and elsewhere.
?Why are loading doses used?
Teicoplanin takes time to reach effective blood levels. One study found five loading doses of 10-12 mg/kg at 12-hour intervals were needed to reach trough levels of 15 to 30 mg/L in patients with normal kidney function.
?Is linezolid better than teicoplanin for hospital pneumonia?
Pooled trials found similar clinical cure rates; one analysis of twelve trials found better bacterial eradication with linezolid, without a significant difference in cure.
?What kidney monitoring is needed?
Teicoplanin caused less nephrotoxicity than vancomycin in pooled trials, and in the loading-dose study nephrotoxicity was 1.3% and 3.3% across two regimens, but kidney function still guides dosing.
?Is it kinder to the kidneys than vancomycin?
The evidence points that way. A meta-analysis of randomised trials found less nephrotoxicity (risk ratio 0.44), and in matched older patients kidney injury occurred in 16.1% on teicoplanin against 32.3% on vancomycin.
?Why are blood levels checked?
Because early levels are often too low. Older adults on standard regimens were mostly underdosed in the first week, and in children troughs below 10 mg/L were linked to treatment success of 50% against 95.7% above it.
?Can it treat infected ports?
In 22 children with cancer and port-related staphylococcal bacteraemia, teicoplanin lock therapy saved 72.7% of ports.
References
- [fda] US FDA, Drugs@FDA via openFDA: search for generic name teicoplanin returned no records. Read October 3, 2026.
- [pubmed] Svetitsky S, et al. "Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis." Antimicrob Agents Chemother, 2009;53(10):4069-79. PMID: 19596875.
- [pubmed] Ueda T, et al. "High-dose regimen to achieve novel target trough concentration in teicoplanin." J Infect Chemother, 2014;20(1):43-7. PMID: 24462424.
- [pubmed] Kalil AC, et al. "Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis." Crit Care Med, 2010;38(9):1802-8. PMID: 20639754.
- [pubmed] Kawasuji H, et al. "Effectiveness and Safety of Linezolid Versus Vancomycin, Teicoplanin, or Daptomycin against Methicillin-Resistant Staphylococcus aureus Bacteremia: A Systematic Review and Meta-Analysis." Antibiotics (Basel), 2023;12(4). PMID: 37107059.
- [pubmed] Jiang H, et al. "Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials." Eur J Clin Microbiol Infect Dis, 2013;32(9):1121-8. PMID: 23568605.
- [pubmed] Marroni M, et al. "Prospective, randomized, double-blind trial comparing teicoplanin and cefazolin as antibiotic prophylaxis in prosthetic vascular surgery." Eur J Clin Microbiol Infect Dis, 1999;18(3):175-8. PMID: 10357049.
- [pubmed] Mohammad S, et al. "Comparative Risk of Acute Kidney Injury with Piperacillin-Tazobactam Plus Teicoplanin Versus Piperacillin-Tazobactam Plus Vancomycin: A Systematic Review and Meta-Analysis." Drug Saf, 2026;49(3):291-302. PMID: 40940625.
- [pubmed] Peng Y, et al. "Teicoplanin as an effective alternative to vancomycin for treatment of MRSA infection in Chinese population: a meta-analysis of randomized controlled trials." PLoS One, 2013;8(11):e79782. PMID: 24260299.
- [pubmed] Wu J, et al. "Comparative renal safety of teicoplanin versus vancomycin in older patients: a propensity-matched multicenter study." Int J Infect Dis, 2026;164:108399. PMID: 41544845.
- [pubmed] Lee JH, et al. "Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia." BMC Infect Dis, 2022;22(1):600. PMID: 35799129.
- [pubmed] Liu T, et al. "Necessity for higher teicoplanin doses in older adults: a multicenter prospective observational study in China." BMC Geriatr, 2024;24(1):487. PMID: 38831261.
- [pubmed] Mariani M, et al. ""Standard" Is More Than Enough: Therapeutic Drug Monitoring Confirms Early Target Attainment of Teicoplanin Regimens in Pediatric Patients." Ther Drug Monit, 2026. PMID: 42208049.
- [pubmed] Okur Acar S, et al. "Efficacy of Teicoplanin Lock Therapy in the Treatment of Port-related Coagulase-negative Staphylococci Bacteremia in Pediatric Oncology Patients." J Pediatr Hematol Oncol, 2023;45(1):e17-e20. PMID: 35700426.
- [pubmed] Hanai Y, et al. "Optimal Teicoplanin Trough Concentration With Therapeutic Drug Monitoring in Children: A Systematic Review and Meta-analysis." Ther Drug Monit, 2024;46(6):699-709. PMID: 39023364.
Sources & Citations
Studies were read from their PubMed abstracts; no US label exists. Read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.